| Literature DB >> 31427331 |
Abdul-Jaleel A Latif Zainel1, Hamda Qotba2, Ahmed Al Nuaimi2, Mohamed Syed2.
Abstract
OBJECTIVES: To investigate the prevalence of vitamin D deficiency among individuals attending primary healthcare facilities in Qatar and to assess the association between vitamin D deficiency and some medical conditions in persons aged 18-65 years old.Entities:
Keywords: Qatar; adults; chronic disease; prevalence; vitamin D
Mesh:
Year: 2019 PMID: 31427331 PMCID: PMC6701579 DOI: 10.1136/bmjopen-2019-029334
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Frequency distribution of the total study sample with an available recorded value for serum vitamin D during the year 2017
| N | % | |
| Age group in years | ||
| 18–29 | 23 348 | 22.8 |
| 30–39 | 30 889 | 30.2 |
| 40–49 | 24 736 | 24.2 |
| 50–65 | 23 369 | 22.8 |
| Total | 102 342 | 100.0 |
| Gender | ||
| Female | 67 393 | 65.9 |
| Male | 34 946 | 34.1 |
| Total | 102 339 | 100.0 |
| Nationality | ||
| Other nationalities | 72 314 | 70.7 |
| Qatari | 30 028 | 29.3 |
| Total | 102 342 | 100.0 |
| Vitamin D therapy before the last serum vitamin D test | ||
| No | 70 818 | 68.9 |
| Yes | 31 903 | 31.1 |
| Total | 102 721 | 100.0 |
| BMI measurement | ||
| Acceptable (<25) | 18 108 | 23.2 |
| Overweight (25–29.9) | 26 523 | 34.0 |
| Grade 1 or low risk obesity (30–34.9) | 19 549 | 25.1 |
| Grade 2 or moderate risk obesity (35–39.9) | 9008 | 11.6 |
| Grade 3 obesity (morbid obesity) (40+) | 4779 | 6.1 |
| Total | 77 967 | 100.0 |
BMI, body mass index.
Figure 1Among study participants with no evidence of prior vitamin D replacement therapy, the prevalence rate of the severe form of vitamin D deficiency (serum level <10 ng/mL) was 14.1% and this rate declined to 3.3% among treated individuals. on the other side, the prevalence rate of vitamin D deficiency (serum level <20 ng/mL) was 71.4% among non-treated study participants compared with 53.4% among treated ones. A third cut-off value for defining vitamin D insufficiency is set at <30 ng/mL, at this level the prevalence rate was as high as 92.7% among the non-treated group reduced slightly to 87.8% among the treated group.
The prevalence of selected outcomes based on different serum vitamin D cut-off values for study participants with no evidence of vitamin D therapy before testing stratified by sociodemographic variables
| Total | Severe vitamin D deficiency | Vitamin D deficiency | Vitamin D insufficiency | ||||
| N | N | % | N | % | N | % | |
| Age group in years | |||||||
| 18–29 | 17 862 | 4712 | 26.4 | 14 610 | 81.8 | 17 036 | 95.4 |
| 30–39 | 22 788 | 2951 | 12.9 | 16 565 | 72.7 | 21 276 | 93.4 |
| 40–49 | 16 808 | 1536 | 9.1 | 11 482 | 68.3 | 15 522 | 92.3 |
| 50–65 | 13 234 | 775 | 5.9 | 7847 | 59.3 | 11 711 | 88.5 |
| Gender | |||||||
| Female | 44 773 | 7459 | 16.7 | 32 649 | 72.9 | 41 328 | 92.3 |
| Male | 25 916 | 2514 | 9.7 | 17 852 | 68.9 | 24 214 | 93.4 |
| Nationality | |||||||
| Other nationalities | 51 158 | 6277 | 12.3 | 36 344 | 71 | 47 905 | 93.6 |
| Qatari | 19 534 | 3697 | 18.9 | 14 160 | 72.5 | 17 640 | 90.3 |
| Season (year quarter) of testing for serum vitamin D | |||||||
| First quarter | 14 691 | 2085 | 14.2 | 10 697 | 72.8 | 13 753 | 93.6 |
| Second quarter | 15 127 | 1807 | 11.9 | 10 682 | 70.6 | 14 092 | 93.2 |
| Third quarter | 18 447 | 2860 | 15.5 | 13 545 | 73.4 | 17 183 | 93.1 |
| Fourth quarter | 22 427 | 3222 | 14.4 | 15 580 | 69.5 | 20 517 | 91.5 |
| BMI (kg/m2) measurement in latest visit | |||||||
| Acceptable (<25) | 13 079 | 2191 | 16.8 | 9224 | 70.5 | 11 997 | 91.7 |
| Overweight (25–29.9) | 17 606 | 2257 | 12.8 | 12 307 | 69.9 | 16 205 | 92.0 |
| Grade 1 or low risk obesity (30–34.9) | 11 987 | 1642 | 13.7 | 8676 | 72.4 | 11 134 | 92.9 |
| Grade 2 or moderate risk obesity (35–39.9) | 5313 | 825 | 15.5 | 4042 | 76.1 | 4967 | 93.5 |
| Grade 3 obesity (morbid obesity) (40+) | 2756 | 488 | 17.7 | 2169 | 78.7 | 2585 | 93.8 |
BMI, body mass index.
The prevalence of severe vitamin D deficiency (<10 ng/mL) among study participants with no evidence of vitamin D replacement therapy before testing by selected explanatory variables after adjusting for age group
| Total | Severe vitamin D deficiency (<10 ng/mL) | ||
| N | N | % | |
|
| |||
| 18–29 years of age | |||
| Female | 13 712 | 3900 | 28.4 |
| Male | 4150 | 812 | 19.6 |
| 30–39 years of age | |||
| Female | 15 121 | 2190 | 14.5 |
| Male | 7666 | 761 | 9.9 |
| 40–49 years of age | |||
| Female | 9528 | 999 | 10.5 |
| Male | 7278 | 536 | 7.4 |
| 50–65 years of age | |||
| Female | 6412 | 370 | 5.8 |
| Male | 6822 | 405 | 5.9 |
|
| |||
| 18–29 years of age | |||
| Other nationalities | 10 884 | 2563 | 23.5 |
| Qatari | 6978 | 2149 | 30.8 |
| 30–39 years of age | |||
| Other nationalities | 18 082 | 2164 | 12.0 |
| Qatari | 4706 | 787 | 16.7 |
| 40–49 years of age | |||
| Other nationalities | 12 815 | 1032 | 8.1 |
| Qatari | 3993 | 504 | 12.6 |
| 50–65 years of age | |||
| Other nationalities | 9377 | 518 | 5.5 |
| Qatari | 3857 | 257 | 6.7 |
|
| |||
| 18–29 years of age | |||
| First quarter | 3683 | 967 | 26.3 |
| Second quarter | 3730 | 910 | 24.4 |
| Third quarter | 5062 | 1393 | 27.5 |
| Fourth quarter | 5387 | 1442 | 26.8 |
| 30–39 years of age | |||
| First quarter | 4903 | 643 | 13.1 |
| Second quarter | 5126 | 536 | 10.5 |
| Third quarter | 5810 | 816 | 14.0 |
| Fourth quarter | 6949 | 956 | 13.8 |
| 40–49 years of age | |||
| First quarter | 3430 | 312 | 9.1 |
| Second quarter | 3551 | 243 | 6.8 |
| Third quarter | 4257 | 442 | 10.4 |
| Fourth quarter | 5570 | 539 | 9.7 |
| 50–65 years of age | |||
| First quarter | 2675 | 163 | 6.1 |
| Second quarter | 2720 | 118 | 4.3 |
| Third quarter | 3318 | 209 | 6.3 |
| Fourth quarter | 4521 | 285 | 6.3 |
|
| |||
| 18–29 years of age | |||
| Acceptable (<25) | 5850 | 1558 | 26.6 |
| Overweight (25–29.9) | 3912 | 982 | 25.1 |
| Grade 1 or low risk obesity (30–34.9) | 2193 | 587 | 26.8 |
| Grade 2 or moderate risk obesity (35–39.9) | 1016 | 316 | 31.1 |
| Obesity grade 3 (morbid obesity) (40+) | 525 | 178 | 33.9 |
| 30–39 years of age | |||
| Acceptable (<25) | 3826 | 443 | 11.6 |
| Overweight (25–29.9) | 6003 | 776 | 12.9 |
| Grade 1 or low risk obesity (30–34.9) | 3904 | 557 | 14.3 |
| Grade 2 or moderate risk obesity (35–39.9) | 1651 | 280 | 17.0 |
| Obesity grade 3 (morbid obesity) (40+) | 785 | 162 | 20.6 |
| 40–49 years of age | |||
| Acceptable (<25) | 1946 | 137 | 7.0 |
| Overweight (25–29.9) | 4239 | 346 | 8.2 |
| Grade 1 or low risk obesity (30–34.9) | 3191 | 340 | 10.7 |
| Grade 2 or moderate risk obesity (35–39.9) | 1339 | 141 | 10.5 |
| Obesity grade 3 (morbid obesity) (40+) | 742 | 97 | 13.1 |
| 50–65 years of age | |||
| Acceptable (<25) | 1457 | 53 | 3.6 |
| Overweight (25–29.9) | 3452 | 153 | 4.4 |
| Grade 1 or low risk obesity (30–34.9) | 2699 | 158 | 5.9 |
| Grade 2 or moderate risk obesity (35–39.9) | 1307 | 88 | 6.7 |
| Obesity grade 3 (morbid obesity) (40+) | 704 | 51 | 7.2 |
|
| |||
| 18–29 years of age | |||
| None of the listed chronic diseases | 14 738 | 3922 | 26.6 |
| Diabetes | 1716 | 431 | 25.1 |
| Hypertension | 575 | 133 | 23.1 |
| Asthma | 1109 | 301 | 27.1 |
| Stroke | 7 | 2 | 28.6 |
| Cardiovascular disease | 47 | 7 | 14.9 |
| Any of the listed chronic diseases | 3124 | 790 | 25.3 |
| 30–39 years of age | |||
| None of the listed chronic diseases | 16 333 | 2161 | 13.2 |
| Diabetes | 4093 | 535 | 13.1 |
| Hypertension | 2135 | 217 | 10.2 |
| Asthma | 1286 | 171 | 13.3 |
| Stroke | 18 | 2 | 11.1 |
| Cardiovascular disease | 101 | 12 | 11.9 |
| Any of the listed chronic diseases | 6455 | 790 | 12.2 |
| 40–49 years of age | |||
| None of the listed chronic diseases | 9166 | 905 | 9.9 |
| Diabetes | 4608 | 390 | 8.5 |
| Hypertension | 4243 | 320 | 7.5 |
| Asthma | 1241 | 108 | 8.7 |
| Stroke | 43 | 5 | 11.6 |
| Cardiovascular disease | 238 | 14 | 5.9 |
| Any of the listed chronic diseases | 7642 | 631 | 8.3 |
| 50–65 years of age | |||
| None of the listed chronic diseases | 3814 | 272 | 7.1 |
| Diabetes | 6603 | 344 | 5.2 |
| Hypertension | 6903 | 349 | 5.1 |
| Asthma | 1441 | 61 | 4.2 |
| Stroke | 88 | 7 | 8.0 |
| Cardiovascular disease | 713 | 38 | 5.3 |
| Any of the listed chronic diseases | 9420 | 503 | 5.3 |
BMI, body mass index.
Discriminant analysis with selected explanatory variables to predict study participants with severe vitamin D deficiency differentiating them from those with serum levels of 10+
| Variables ordered by absolute size of correlation (pooled within-groups correlations between discriminating variables and standardised canonical discriminant functions) within function | Risk of having severe Vitamin D deficiency | |
| Age in year | 1 | Decrease |
| Hypertension | 2 | Increase |
| Male versus Female Gender | 3 | Decrease |
| Qatari Nationality versus Others | 4 | Increase |
| Diabetes | 5 | Decrease |
| Cardiovascular disease | 6 | Increase |
| Asthma | 7 | Decrease |
| Stroke | 8 | Increase |
| BMI measurement | 9 | Increase |
BMI, body mass index.
| Unstandardised coefficients | |
| Gender (male coded as one and females as zero) | 0.310 |
| Age in year | 0.081 |
| BMI measurement in latest visit | −0.026 |
| Nationality (Qatari coded as one and others as zero) | −0.531 |
| Diabetes (coded as one when present and zero if absent) | 0.022 |
| Hypertension (coded as one when present and zero if absent) | −0.006 |
| Asthma (coded as one when present and zero if absent) | 0.154 |
| Stroke (coded as one when present and zero if absent) | −0.345 |
| Cardiovascular disease (coded as one when present and zero if absent) | −0.188 |
| (Constant) | −2.296 |
D=−2.296+[0.31x(Gender)]+[0.081x(Age in year)]+[−0.026x(BMI Measurement in latest visit)]+[−0.531x (Nationality)]+[0.022x(Diabetes)]+[−0.006x(Hypertension)] [0.154x(Asthma)]+[−0.345x(Stroke)]+[−0.188×(Cardiovascular disease)].
Discriminant score (D)=−0.245. If D<−0.245 then the individual is expected to have severe vitamin D deficiency.